MRSA

Drug maker Melinta has submitted their new antibiotic Baxdela for review by the US Food and Drug Administration, with the hopes that it will bring a new treatment option for people suffering from methicillin-resistant Staphylococcus aureus (MRSA).

Methicillin-resistant Staphylococcus aureus (MRSA) causes more than 11,000 deaths in the United States each year and a new study shows how this pathogen is able to evade last-line antibiotics.

Susan Kline, MD, MPH, associate professor of medicine, Division of Infectious Diseases and International Medicine, medical director for Infection Control, lead physician for Antibiotic Stewardship, at the University of Minnesota, discusses the growing problem of antibiotic-resistance in hospital-acquired infections.

In a recent study in mice, researchers used a synthetic peptide to disrupt the bacterial stress response that causes abscess formation in skin infections with drug-resistant bacteria.

On September 21, 2016, delegates at the 71st meeting of the United Nations (UN) General Assembly gathered to discuss the shared danger of antimicrobial resistance, signaling the global scale of this urgent public health crisis while pledging to collectively tackle the problem of superbugs.

Health officials around the world agree that our one of the best steps to reducing the problem of antimicrobial resistance is scaling back on unnecessary overprescribing of these medications. As doctors in many countries work to implement these efforts, a new report out of the United Kingdom shows some progress in the fight against drug-resistant “superbugs,” along with plenty of work to still be done.

When the colistin-resistant gene, mcr-1, was first found in China in 2015, health officials around the world knew that the gene would inevitably appear in their countries. It has since been detected in other parts of Asia, Europe, and North America, including Canada, which just released a 2016 report from their Canadian Antimicrobial Resistance Surveillance System.

John D'Angelo, MD, senior vice president, executive director of Emergency Medicine Services at Northwell Health, describes how hospital clinicians can identify and treat patients at highest risk for contracting antibiotic-resistant infections.

Nearly a decade ago, 130 Veterans Health Administration facilities around the country introduced their methicillin-resistant Staphylococcus aureus (MRSA) Preventive Initiative to reduce transmission of the “superbug” in their hospitals and health centers.

In a new ruling, the US Food and Drug Administration (FDA) has declared that companies selling over-the-counter antiseptic washes will no longer be allowed to market their products as such due to doubts over these products’ safety and effectiveness.

New research from the Imperial College of London now offers a promising novel approach in the fight against methicillin-resistant Staphylococcus aureus (MRSA), and their findings are decidedly salty.

As the rise of antibiotic-resistant bacteria leads to higher rates of life-threatening infections from pathogens such Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA), researchers are increasingly looking to probiotic treatment as an important part of fighting infections.

Wound care is challenging in today’s era of antibiotic-resistant bacterial infections, but healthcare practitioners treating infectious wounds have some tiny allies.

Robin Jump, MD, PhD, assistant professor in the Department of Medicine at the Case Western Reserve University, discusses efforts to screen asymptomatic Clostridium difficile carriers as well as some of the barriers to implementing active surveillance and putting asymptomatic carriers in isolation.

According to the new study, the antibacterial response of white blood cells to the flu virus fails to target the S. aureus bacteria and instead causes inflammatory injury to the lungs and damage to surrounding tissue, creating a higher susceptibility to secondary bacterial infections such as MRSA pneumonia.

Jeff Boyd, PhD, assistant professor of Biochemistry and Microbiology at Rutgers School of Environmental and Biological Sciences, explains the metal-resistance processes of microbes.

Michael Calderwood, MD, MPH, previously assistant hospital epidemiologist and associate director of antimicrobial stewardship at Brigham and Women’s Hospital, outlines ways in which infection prevention strategies can be modified to fit the needs of immunocompromised individuals.

A new study conducted by Andreas Peschel, PhD, and colleagues at the University of Tuebingen in Germany, has shown that lugdunin, a bacteria naturally produced by the human body, can be used as an antibiotic that can eliminate Methicillin-Resistant Staphylococcus aureus (MRSA).

Jeff Boyd, PhD, assistant professor of Biochemistry and Microbiology at Rutgers school of Environmental and Biological Sciences, explains how Staphylococcus aureus and other microbes become antibiotic-resistant.

Jeff Boyd, PhD, assistant professor of Biochemistry and Microbiology at Rutgers School of Environmental and Biological Sciences, explains the difference between Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus.

Researchers at Jiangsu University in China have demonstrated that whole genome sequencing can be used to confirm findings from traditional bacterial genotyping methods to identify outbreaks of MRSA and control nosocomial transmission.

On March 8, 2016, researchers at the Ulsan National Institute of Science and Technology reported the development of an antibacterial fabric that inhibits the growth of bacteria, including antibiotic-resistant bacteria.

The Centers for Disease Control and Prevention believes far too many Americans are exposed to "dangerous, drug-resistant bacteria" in hospitals and other healthcare settings.

Study finds no evidence that long-term daily use of CHG leads to high levels of antibiotic resistance in bacteria on patients' skin.

After swabbing 20 beards, more than 100 bacteria growths were identified.